Kyung Dong Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Kyung Dong Pharmaceutical has a total shareholder equity of ₩218.6B and total debt of ₩40.0B, which brings its debt-to-equity ratio to 18.3%. Its total assets and total liabilities are ₩290.4B and ₩71.8B respectively.
Key information
18.3%
Debt to equity ratio
₩39.98b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩29.50b |
| Equity | ₩218.55b |
| Total liabilities | ₩71.84b |
| Total assets | ₩290.39b |
Recent financial health updates
Is Kyung Dong Pharmaceutical (KOSDAQ:011040) A Risky Investment?
Mar 07
We Think Kyung Dong Pharmaceutical (KOSDAQ:011040) Can Manage Its Debt With Ease
Dec 05Recent updates
Is Kyung Dong Pharmaceutical (KOSDAQ:011040) A Risky Investment?
Mar 07Consider This Before Buying Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) For The 1.9% Dividend
Feb 18
Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Share Price Gain of 27% Match Its Business Performance?
Feb 03Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Statutory Profit Adequately Reflect Its Underlying Profit?
Jan 19Kyung Dong Pharmaceutical Co., Ltd.'s (KOSDAQ:011040) Dismal Stock Performance Reflects Weak Fundamentals
Jan 04How Much Of Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) Do Insiders Own?
Dec 20We Think Kyung Dong Pharmaceutical (KOSDAQ:011040) Can Manage Its Debt With Ease
Dec 05Financial Position Analysis
Short Term Liabilities: A011040's short term assets (₩90.9B) exceed its short term liabilities (₩67.2B).
Long Term Liabilities: A011040's short term assets (₩90.9B) exceed its long term liabilities (₩4.7B).
Debt to Equity History and Analysis
Debt Level: A011040's net debt to equity ratio (4.8%) is considered satisfactory.
Reducing Debt: A011040's debt to equity ratio has increased from 8.3% to 18.3% over the past 5 years.
Debt Coverage: A011040's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if A011040's interest payments on its debt are well covered by EBIT.